Syringaresinol protects against hypoxia/reoxygenation-induced cardiomyocytes injury and death by destabilization of HIF-1a in a FOXO3-dependent mechanism

Siyoung Cho, Miook Cho, Juewon Kim, Matt Kaeberlein, Sang Jun Lee, Yousin Suh

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Hypoxia-inducible factor 1 (HIF-1) is a master regulator of hypoxic response and has been a prime therapeutic target for ischemia/reperfusion (I/R)-derived myocardial dysfunction and tissue damage. There is also increasing evidence that HIF-1 plays a central role in regulating aging, both through interactions with key longevity factors including Sirtuins and mTOR, as well as by directly promoting longevity in Caenorhabditis elegans. We investigated a novel function and the underlying mechanism of syringaresinol, a lignan compound, in modulation of HIF- 1 and protection against cellular damage and death in a cardiomyocyte model of I/R injury. Syringaresinol caused destabilization of HIF-1a following H/R and then protected against hypoxia/reoxygenation (H/R)-induced cellular damage, apoptosis, and mitochondrial dysfunction in a dose-dependent manner. Knock-down of FOXO3 by specific siRNAs completely abolished the ability of syringaresinol to inhibit HIF- 1 stabilization and apoptosis caused by H/R. Syringaresinol stimulated the nuclear localization and activity of FOXO3 leading to increased expression of antioxidant genes and decreased levels of reactive oxygen species (ROS) following H/R. Our results provide a new mechanistic insight into a functional role of syringaresinol against H/R-induced cardiomyocyte injury and death. The degradation of HIF-1a through activation of FOXO3 is a potential therapeutic strategy for ischemia-related diseases.

Original languageEnglish (US)
Pages (from-to)43-55
Number of pages13
JournalOncotarget
Volume6
Issue number1
StatePublished - 2015

Fingerprint

Cardiac Myocytes
Wounds and Injuries
Hypoxia-Inducible Factor 1
Ischemia
Sirtuins
Apoptosis
Lignans
Myocardial Reperfusion
Caenorhabditis elegans
Reperfusion Injury
Reactive Oxygen Species
Antioxidants
Hypoxia
syringaresinol
Gene Expression
Therapeutics

Keywords

  • Cardiomyocytes
  • FOXO3
  • HIF-1a
  • Hypoxia/reoxygenation
  • Ischemia/reperfusion
  • Syringaresinol

ASJC Scopus subject areas

  • Oncology

Cite this

Syringaresinol protects against hypoxia/reoxygenation-induced cardiomyocytes injury and death by destabilization of HIF-1a in a FOXO3-dependent mechanism. / Cho, Siyoung; Cho, Miook; Kim, Juewon; Kaeberlein, Matt; Lee, Sang Jun; Suh, Yousin.

In: Oncotarget, Vol. 6, No. 1, 2015, p. 43-55.

Research output: Contribution to journalArticle

Cho, Siyoung ; Cho, Miook ; Kim, Juewon ; Kaeberlein, Matt ; Lee, Sang Jun ; Suh, Yousin. / Syringaresinol protects against hypoxia/reoxygenation-induced cardiomyocytes injury and death by destabilization of HIF-1a in a FOXO3-dependent mechanism. In: Oncotarget. 2015 ; Vol. 6, No. 1. pp. 43-55.
@article{d24142dbdb2c4c7385441691bf3a1266,
title = "Syringaresinol protects against hypoxia/reoxygenation-induced cardiomyocytes injury and death by destabilization of HIF-1a in a FOXO3-dependent mechanism",
abstract = "Hypoxia-inducible factor 1 (HIF-1) is a master regulator of hypoxic response and has been a prime therapeutic target for ischemia/reperfusion (I/R)-derived myocardial dysfunction and tissue damage. There is also increasing evidence that HIF-1 plays a central role in regulating aging, both through interactions with key longevity factors including Sirtuins and mTOR, as well as by directly promoting longevity in Caenorhabditis elegans. We investigated a novel function and the underlying mechanism of syringaresinol, a lignan compound, in modulation of HIF- 1 and protection against cellular damage and death in a cardiomyocyte model of I/R injury. Syringaresinol caused destabilization of HIF-1a following H/R and then protected against hypoxia/reoxygenation (H/R)-induced cellular damage, apoptosis, and mitochondrial dysfunction in a dose-dependent manner. Knock-down of FOXO3 by specific siRNAs completely abolished the ability of syringaresinol to inhibit HIF- 1 stabilization and apoptosis caused by H/R. Syringaresinol stimulated the nuclear localization and activity of FOXO3 leading to increased expression of antioxidant genes and decreased levels of reactive oxygen species (ROS) following H/R. Our results provide a new mechanistic insight into a functional role of syringaresinol against H/R-induced cardiomyocyte injury and death. The degradation of HIF-1a through activation of FOXO3 is a potential therapeutic strategy for ischemia-related diseases.",
keywords = "Cardiomyocytes, FOXO3, HIF-1a, Hypoxia/reoxygenation, Ischemia/reperfusion, Syringaresinol",
author = "Siyoung Cho and Miook Cho and Juewon Kim and Matt Kaeberlein and Lee, {Sang Jun} and Yousin Suh",
year = "2015",
language = "English (US)",
volume = "6",
pages = "43--55",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "1",

}

TY - JOUR

T1 - Syringaresinol protects against hypoxia/reoxygenation-induced cardiomyocytes injury and death by destabilization of HIF-1a in a FOXO3-dependent mechanism

AU - Cho, Siyoung

AU - Cho, Miook

AU - Kim, Juewon

AU - Kaeberlein, Matt

AU - Lee, Sang Jun

AU - Suh, Yousin

PY - 2015

Y1 - 2015

N2 - Hypoxia-inducible factor 1 (HIF-1) is a master regulator of hypoxic response and has been a prime therapeutic target for ischemia/reperfusion (I/R)-derived myocardial dysfunction and tissue damage. There is also increasing evidence that HIF-1 plays a central role in regulating aging, both through interactions with key longevity factors including Sirtuins and mTOR, as well as by directly promoting longevity in Caenorhabditis elegans. We investigated a novel function and the underlying mechanism of syringaresinol, a lignan compound, in modulation of HIF- 1 and protection against cellular damage and death in a cardiomyocyte model of I/R injury. Syringaresinol caused destabilization of HIF-1a following H/R and then protected against hypoxia/reoxygenation (H/R)-induced cellular damage, apoptosis, and mitochondrial dysfunction in a dose-dependent manner. Knock-down of FOXO3 by specific siRNAs completely abolished the ability of syringaresinol to inhibit HIF- 1 stabilization and apoptosis caused by H/R. Syringaresinol stimulated the nuclear localization and activity of FOXO3 leading to increased expression of antioxidant genes and decreased levels of reactive oxygen species (ROS) following H/R. Our results provide a new mechanistic insight into a functional role of syringaresinol against H/R-induced cardiomyocyte injury and death. The degradation of HIF-1a through activation of FOXO3 is a potential therapeutic strategy for ischemia-related diseases.

AB - Hypoxia-inducible factor 1 (HIF-1) is a master regulator of hypoxic response and has been a prime therapeutic target for ischemia/reperfusion (I/R)-derived myocardial dysfunction and tissue damage. There is also increasing evidence that HIF-1 plays a central role in regulating aging, both through interactions with key longevity factors including Sirtuins and mTOR, as well as by directly promoting longevity in Caenorhabditis elegans. We investigated a novel function and the underlying mechanism of syringaresinol, a lignan compound, in modulation of HIF- 1 and protection against cellular damage and death in a cardiomyocyte model of I/R injury. Syringaresinol caused destabilization of HIF-1a following H/R and then protected against hypoxia/reoxygenation (H/R)-induced cellular damage, apoptosis, and mitochondrial dysfunction in a dose-dependent manner. Knock-down of FOXO3 by specific siRNAs completely abolished the ability of syringaresinol to inhibit HIF- 1 stabilization and apoptosis caused by H/R. Syringaresinol stimulated the nuclear localization and activity of FOXO3 leading to increased expression of antioxidant genes and decreased levels of reactive oxygen species (ROS) following H/R. Our results provide a new mechanistic insight into a functional role of syringaresinol against H/R-induced cardiomyocyte injury and death. The degradation of HIF-1a through activation of FOXO3 is a potential therapeutic strategy for ischemia-related diseases.

KW - Cardiomyocytes

KW - FOXO3

KW - HIF-1a

KW - Hypoxia/reoxygenation

KW - Ischemia/reperfusion

KW - Syringaresinol

UR - http://www.scopus.com/inward/record.url?scp=84921391894&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921391894&partnerID=8YFLogxK

M3 - Article

C2 - 25415049

AN - SCOPUS:84921391894

VL - 6

SP - 43

EP - 55

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 1

ER -